Pfizer identifies emerging markets for future growth
This article was originally published in Scrip
Pfizerplans to offset the generic erosion of Lipitor (simvastatin) sales by driving growth in emerging markets and reworking its sales operations. Pfizer’s president of worldwide pharmaceutical operations, Ian Read, outlined the plan at the UBS global life science conference before addressing the future of the cholesterol drug.
You may also be interested in...
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.